表紙
市場調查報告書

醫藥品分析:Farxiga

Farxiga

出版商 Datamonitor Healthcare 商品編碼 603953
出版日期 內容資訊 英文 54 Pages
商品交期: 最快1-2個工作天內
價格
醫藥品分析:Farxiga Farxiga
出版日期: 2019年02月07日內容資訊: 英文 54 Pages
簡介

Farxiga (dapagliflozin) ,是對鈉、葡萄糖共同輸送體2 (SGLT2) 的抑制劑,作為第二型糖尿病的治療藥被承認,作為第一型糖尿病的治療藥是第三階段試驗中。

本報告提供Farxiga (dapagliflozin) 調查分析,產品簡介相關的系統性資訊。

產品簡介

  • Farxiga :第二型糖尿病
  • Farxiga :第一型糖尿病

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0080869

Overview

Farxiga (dapagliflozin; AstraZeneca/Ono Pharmaceutical) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including diabetic nephropathy. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy, they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
    • Farxiga: Diabetic nephropathy
    • Farxiga: Diabetes type 1
    • Farxiga: Chronic heart failure (CHF)
    • Farxiga: Diabetes type 2

LIST OF FIGURES

  • Figure 1: Datamonitor Healthcare's drug assessment summary of Farxiga for diabetic nephropathy
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Farxiga for diabetic nephropathy
  • Figure 3: Farxiga sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 4: Farxiga for type 1 diabetes - SWOT analysis
  • Figure 5: Datamonitor Healthcare's drug assessment of Farxiga in type 1 diabetes
  • Figure 6: Datamonitor Healthcare's drug assessment of Farxiga in type 1 diabetes
  • Figure 7: Farxiga for chronic heart failure - SWOT analysis
  • Figure 8: Datamonitor Healthcare's drug assessment summary of Farxiga for chronic heart failure
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Farxiga for chronic heart failure
  • Figure 10: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 11: Farxiga for type 2 diabetes - SWOT analysis
  • Figure 12: Datamonitor Healthcare drug assessment of Farxiga
  • Figure 13: Datamonitor Healthcare drug assessment scorecard for Farxiga compared to Januvia
  • Figure 14: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 15: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Table 1: Farxiga drug profile
  • Table 2: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
  • Table 3: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
  • Table 4: Farxiga for diabetic nephropathy - SWOT analysis
  • Table 5: Farxiga drug profile
  • Table 6: Farxiga late-phase trials in type 1 diabetes
  • Table 7: Farxiga drug profile
  • Table 8: Farxiga Phase III trials in chronic heart failure
  • Table 9: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 10: Farxiga franchise products
  • Table 11: Farxiga drug profile
  • Table 12: Xigduo drug profile
  • Table 13: Overview of pivotal trial data for Farxiga in diabetes
  • Table 14: Key planned and ongoing Phase III clinical trials for Farxiga in diabetes
  • Table 15: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 16: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25